Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204723 | 1.00 | UTS2R (0.36) | UTS2RCTSKRIPK1KMT2AUSP30 | |
| SCHEMBL6204721 | 1.00 | UTS2R (0.36) | UTS2RCTSKRIPK1KMT2AUSP30 | |
| SCHEMBL5781257 | 0.96 | UTS2R (0.35) | UTS2RCTSKRIPK1KMT2AUSP30 | |
| SCHEMBL5781254 | 0.96 | UTS2R (0.35) | UTS2RCTSKRIPK1KMT2AUSP30 | |
| SCHEMBL6204257 | 0.96 | UTS2R (0.35) | UTS2RCTSKRIPK1KMT2AUSP30 | |
| SCHEMBL6204252 | 0.96 | UTS2R (0.35) | UTS2RCTSKRIPK1KMT2AUSP30 | |
| SCHEMBL6204249 | 0.96 | UTS2R (0.35) | UTS2RCTSKRIPK1KMT2AUSP30 | |
| SCHEMBL6204711 | 0.82 | KMT2A (0.41) | UTS2RCTSKKMT2ACTSSATM | |
| SCHEMBL6204716 | 0.82 | KMT2A (0.41) | UTS2RCTSKKMT2ACTSSATM | |
| SCHEMBL6204713 | 0.82 | KMT2A (0.41) | UTS2RCTSKKMT2ACTSSATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020459-B1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-20020077345-A1 | Cis-substituted aminocycloalkylpyrrolidine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-06-20 | — | — | US | disclosed |
| US-6184388-B1 | ANTIBACTERIAL AND ANTIMICROBIAL, QUINOLINE ANTIBIOTIC | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-02-06 | — | — | US | disclosed |
| US-6121285-A | 5-AMINO-7-(4-(1-AMINOCYCLOPROPYL-3-FLUORO-1-PYRROLIDINYL)-6 -FLUORO-1-(2-FLUORO-1-CYCLOPROPYL)-1,4-DIHYDRO-8-METHOXY-4-OXOQUINOLINE-3 -CARBOXYLIC ACID, FOR EXAMPLE; ANTIMICROBIAL DRUGS WITH HIGH SAFETY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-1020459-A1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077345-A1 | Cis-substituted aminocycloalkylpyrrolidine derivatives | Q6ZSR9, ARG1, ASNS | UTS2R 1096/4885CTSK 498/4885RIPK1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.